Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribonuclease MRP subunit p64 (RMP64) is a recently characterized, poorly understood protein component unique to the human RNase MRP ribonucleoprotein complex, an endoribonuclease essential for precursor ribosomal RNA (pre-rRNA) processing at the ITS1 site 2 in the nucleolus[1]. RMP64, together with another unique subunit (RMP24), is required for proper pre-rRNA maturation but is not necessary for RNase P activity and does not associate with the RNase P-specific H1 RNA, highlighting functional specialization[1]. It is predicted to participate in the regulation of neural progenitor differentiation and in the positive regulation of the Notch signaling pathway[2][3]. RMP64 is not an independent enzyme or receptor, nor is it a recognized therapeutic target, but rather a functional subunit of a non-coding ribonucleoprotein complex. Mutations impairing RNase MRP function (primarily through the RNA component) can lead to a spectrum of developmental and skeletal disorders, although specific roles of individual protein subunits, including RMP64, in human disease have not been defined[4].
No direct drug mechanism described or drugs known to target RMP64
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonuclease MRP subunit p64 (RMP64).